Carisma advances macrophage immunotherapy

By The Science Advisory Board staff writers

July 27, 2020 -- Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug (IND) application through the U.S. Food and Drug Administration. The company intends to initiate a phase I clinical trial for the candidate this year.

The company's lead candidate, CT-0508, is a chimeric antigen receptor macrophage (CAR-M) that is targeted at anti-human epidermal growth factor receptor 2 (HER2). The phase I clinical trial will be evaluated in patients with recurrent or metastatic HER2 overexpressing solid tumors after failure of approved HER2-targeted agents. The clinical trials will be conducted at two trial sites at the University of Pennsylvania and the University of North Carolina at Chapel Hill.

Preclinical findings suggest that the company's CAR-M therapy could provide broad immune responses against solid tumors. The acceptance of the IND marks Carisma's transition from a discovery-based firm to a clinical development stage company.

The company also announced that it has expanded its board of directors and scientific advisory board.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.